Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Our previous studies showed that colorectal tumor has high interleukin-4 receptor α (IL-4Rα) expression, whereas adjacent normal tissue has low or no IL-4Rα expression. We also observed that human atherosclerotic plaque-specific peptide-1 (AP1) can specifically target to IL-4Rα. In this study, we investigated the therapeutic efficacy and systemic toxicity of AP1-conjuagted liposomal doxorubicin. AP1 bound more strongly to and was more efficiently internalized into IL-4Rα-overexpressing CT26 cells than CT26 control cells. Selective cytotoxicity experiment revealed that AP1-conjugated liposomal doxorubicin preferentially killed IL-4Rα-overexpressing CT26 cells. AP1-conjugated liposomal doxorubicin administered intravenously into mice produced significant inhibition of tumor growth and showed decreased cardiotoxicity of doxorubicin. These results indicated that AP1-conjugated liposomal doxorubicin has a potent and selective anticancer potential against IL-4Rα-overexpressing colorectal cancer cells, thus providing a model for targeted anticancer therapy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4846110 | PMC |
| http://dx.doi.org/10.1080/15384047.2015.1095397 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Kaposi sarcoma (KS) is an angioproliferative malignancy associated with human herpesvirus 8 (HHV-8) infection, predominantly affecting immunocompromised patients such as those with HIV/AIDS. Despite advances in antiretroviral therapy, KS remains a significant cause of morbidity and mortality in this population, especially when diagnosis or treatment is delayed. Ocular involvement, although rare, can lead to significant functional impairment.
View Article and Find Full Text PDFTriple-Negative Breast Cancer Presenting as Recurrent Cystic Lesions During Lactation: A Case Report.
Clin Case Rep
September 2025
Department of Thoracic Surgery, Fu Xing Hospital, the Eighth Clinical Medical College Capital Medical University Beijing China.
Lactation-associated breast cancer poses diagnostic challenges due to physiological breast changes that may mask malignancies. Triple-negative breast cancer (TNBC) during lactation is rare and aggressive, requiring vigilant evaluation and treatment. This report highlights the diagnostic dilemma of recurrent cystic breast lesions during lactation, which can mimic benign conditions like galactoceles but may conceal aggressive TNBC, leading to potential delays in diagnosis despite initial conservative approaches such as aspiration.
View Article and Find Full Text PDFHIV-Associated Multicentric Castleman Disease with Kaposi Sarcoma: A Case Report with 120-Week Follow-Up of HHV-8 After Remission.
J Infect Chemother
September 2025
AIDS Clinical Center, National Center for Global Health and Medicine, Tokyo, Japan; Center for AIDS Research, Kumamoto University, Kumamoto, Japan.
HIV-associated multicentric Castleman disease (HIV-MCD) is a rare, life-threatening lymphoproliferative disorder featuring systemic inflammation and marked lymphadenopathy. HIV-MCD is characterized by a human herpesvirus-8 (HHV-8) infection, with an increasing incidence despite advances in antiretroviral therapy (ART). Although HHV-8 viremia is a recognized indicator of disease recurrence, the necessity of intervention for low-level viremia reactivation remains unclear.
View Article and Find Full Text PDFPET imaging for non-invasive monitoring of Zr-Talidox delivery to the brain following focused ultrasound-mediated blood-brain barrier opening.
J Control Release
September 2025
Research Department of Imaging Chemistry and Biology, School of Biomedical Engineering & Imaging Sciences, King's College London, London, United Kingdom. Electronic address:
The blood-brain barrier (BBB) significantly hinders the treatment of central nervous system (CNS) disorders and brain tumors with intact BBB by restricting the entry of most therapeutic agents, including small-molecule drugs and particularly larger macromolecules. Liposomal formulations, such as PEGylated liposomes with long blood half-lives, high drug-carrying capacity, and reduced off-site toxicity, can be useful for brain drug delivery, but their large size often limits BBB penetration. A novel liposomal doxorubicin formulation(Talidox®) with a smaller size (~36 nm, determined by TEM), increased blood circulation half-life (median reported half-life 96 h), and better stability than previous clinical formulations, can be a suitable choice for brain delivery.
View Article and Find Full Text PDFTLD: An optimized liposomal doxorubicin formulation with small vesicle size for improved anti-tumor efficacy.
Eur J Pharm Sci
August 2025
InnoMedica Schweiz AG, Gesellschaftsstrasse 16, 3012 Bern, Switzerland. Electronic address:
Talidox (TLD) is an innovative liposomal doxorubicin formulation designed to enhance drug delivery efficiency and reduce systemic toxicity over existing liposomal doxorubicin formulations. This publication consolidates 10 years of preclinical research on TLD, integrating physicochemical characterization, and in vitro and in vivo efficacy. TLD has a reduced particle size and optimized drug-to-lipid ratio compared to Caelyx, aiming to improve tumor penetration and uptake and therefore therapeutic efficacy.
View Article and Find Full Text PDF